10-Q: Certara Q3 2025: Revenue Up 10%, Net Income Rebounds

Certara, Inc. reported a 10% increase in total revenues for Q3 2025, reaching $104.6 million, and a significant rebound to net income of $1.5 million from a net loss in the prior year.

Summary

• Total revenues increased 10% to $104.6 million for the three months ended September 30, 2025, compared to $94.8 million in the same period of 2024.
• Total revenues increased 11% to $315.2 million for the nine months ended September 30, 2025, compared to $284.8 million in the same period of 2024.
• Net income was $1.5 million for the three months ended September 30, 2025, a significant improvement from a net loss of $1.4 million in Q3 2024.
• Net income was $4.3 million for the nine months ended September 30, 2025, compared to a net loss of $18.6 million in the same period of 2024.
• Software revenues grew 22% to $43.8 million in Q3 2025, partly driven by a business acquisition.
• Services revenues increased 3% to $60.8 million in Q3 2025.
• Adjusted EBITDA for Q3 2025 was $35.2 million, up from $33.1 million in Q3 2024.
• Adjusted diluted EPS for Q3 2025 was $0.14, up from $0.13 in Q3 2024.
• Net cash provided by operating activities for the nine months ended September 30, 2025, was $67.5 million, a substantial increase from $31.1 million in the prior year period.
• The company repurchased 3,023,677 shares of common stock for $38.7 million under a $100 million program, with $61.3 million remaining available.
• A Sixth Amendment to the Credit Agreement was entered into in October 2025, reducing the applicable interest rate for term loans.
• The U.S. federal government experienced a shutdown on October 1, 2025, which could lead to delays in regulatory reviews and approvals.
• The 'One Big Beautiful Bill Act' (OBBBA), enacted on July 4, 2025, introduced significant U.S. tax law changes, which the company is currently evaluating for impact.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and a return to profitability, coupled with increased operating cash flow and strategic investments in AI and acquisitions. However, macroeconomic uncertainties and potential impacts from a government shutdown present some headwinds.

Positives

• Strong revenue growth: 10% for Q3 2025 and 11% for the nine months ended September 30, 2025, driven by business acquisitions and increased demand from existing and new customers.
• Return to net income: $1.5 million in Q3 2025 and $4.3 million for the nine months ended September 30, 2025, reversing net losses from the prior year periods.
• Significant increase in net cash provided by operating activities: $67.5 million for the nine months ended September 30, 2025, up from $31.1 million in the prior year, indicating improved operational efficiency and cash generation.
• Robust software revenue growth: 22% increase in Q3 2025, partly attributed to the strategic acquisition of Chemaxon.
• High customer retention: Net Retention Rates of 103.9% in Q3 2025, demonstrating strong customer loyalty and expansion within the existing base.
• Shareholder value return: The Board-approved stock repurchase program led to $38.7 million in common stock repurchases, with $61.3 million remaining.
• Reduced interest expense: A decrease of $0.2 million in Q3 2025 and $1.9 million for the nine months ended September 30, 2025, primarily due to declining market interest rates and a reduced base margin rate from term loan refinancing.
• Favorable debt terms: The Sixth Amendment to the Credit Agreement in October 2025 further reduced applicable interest rates on term loans.
• Compliance with debt covenants: The company was in compliance with all covenants of its Credit Agreement as of September 30, 2025.
• Strategic AI integration: Continued investment in AI and machine learning technologies across software and services portfolios is expected to enhance accuracy and streamline processes.

Negatives

• Potential impact of government shutdown: The U.S. federal government shutdown on October 1, 2025, could lead to prolonged delays or disruptions in regulatory reviews and approvals, adversely affecting operations and financials.
• Increased income tax expense: A provision for income taxes of $6.2 million for the nine months ended September 30, 2025, compared to a benefit of $0.7 million in the prior year period.
• Decreased interest income: A $1.3 million decrease in Q3 2025 and a $3.5 million decrease for the nine months ended September 30, 2025, compared to the prior year periods.
• Rising cost of revenues: Increased by $2.5 million (7%) in Q3 2025 and $5.7 million (5%) for the nine months ended September 30, 2025.
• Higher sales and marketing expenses: Increased by $1.7 million (15%) in Q3 2025 and $5.5 million (16%) for the nine months ended September 30, 2025, partly due to headcount growth and commercial organization investment.
• Increased research and development expenses: Rose by $2.0 million (24%) in Q3 2025 and $0.4 million (1%) for the nine months ended September 30, 2025, driven by investments in software development and AI integration.
• Increased net cash used in investing activities: An increase of $4.3 million for the nine months ended September 30, 2025, primarily due to higher capitalized software development costs.
• Increased net cash used in financing activities: A $39.5 million increase for the nine months ended September 30, 2025, largely due to the common stock repurchase program.
• Strategic review of regulatory services business: An initiated review process in 2024 to evaluate long-term strategic options for this business could potentially have a significant impact on operations.

Risks

• Any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery and development.
• Ability to compete within the market.
• Changes or delays in government regulation relating to the biopharmaceutical industry.
• Trends in research and development (R&D) spending, the use of third parties by biopharmaceutical companies and a shift toward more R&D occurring at smaller biotechnology companies.
• Consolidation within the biopharmaceutical industry.
• Ability to successfully increase customer base, expand relationships and the products and services provided, and enter new markets.
• Ability to retain key personnel or recruit additional qualified personnel.
• Risks related to the mischaracterization of independent contractors.
• Any delays or defects in the release of new or enhanced software or other biosimulation tools.
• Issues relating to the use of artificial intelligence and machine learning in products and services.
• Failure of existing customers to renew software licenses or any delays or terminations of contracts or reductions in scope of work by existing customers.
• Risks related to contracts with government customers, including the ability of third parties to challenge receipt of such contracts.
• Ability to sustain historic growth rates.
• Any future acquisitions and ability to successfully integrate such acquisitions.
• Accuracy of addressable market estimates.
• Ability to successfully operate a global business.
• Adverse global economic conditions, including inflation, tariffs and/or trade disputes and fluctuating interest rates.
• Ability to comply with applicable anti-corruption, trade compliance and economic sanctions laws and regulations.
• Risks related to litigation against the company.
• Adequacy of insurance coverage and ability to obtain adequate insurance coverage in the future.
• Ability to perform services in accordance with contractual requirements, regulatory standards and ethical considerations.
• Loss of more than one major customer.
• The ability or inability of bookings to accurately predict future revenue and ability to realize the anticipated revenue reflected in bookings.
• Any disruption in the operations of third-party providers who host software solutions or any limitations on their capacity or interference with use.
• Ability to reliably meet data storage and management requirements, or the experience of any failures or interruptions in the delivery of services over the internet.
• Any unauthorized access to or use of customer or other proprietary or confidential data or other breach of cybersecurity measures.
• The occurrence of natural disasters, pandemics, epidemic diseases, and public health crises, which may result in delays or cancellations of customer contracts or decreased utilization by employees.
• Ability to comply with the terms of any licenses governing use of third-party open source software utilized in software solutions.
• Ability to comply with applicable privacy and cybersecurity laws.
• Ability to adequately enforce or defend ownership and use of intellectual property and other proprietary rights.
• Any allegations of infringing, misappropriating or otherwise violating a third party's intellectual property rights.
• Ability to meet obligations under current or future indebtedness as they become due.
• Any limitations on ability to pursue business strategies due to restrictions under current or future indebtedness or inability to comply with any restrictions under such indebtedness.
• Any impairment of goodwill or other intangible assets.
• Accuracy of estimates and judgments relating to critical accounting policies and any changes in financial reporting standards or interpretations.
• Any inability to design, implement, and maintain effective internal controls when required by law, or inability to timely remediate internal controls that are deemed ineffective.
• The U.S. federal government shutdown on October 1, 2025, could increase uncertainty in the overall economic environment and adversely impact business operations across multiple industries, including the pharmaceutical industry, leading to prolonged delays or disruptions in regulatory reviews, approvals, or filings.
• The internal review process initiated in 2024 to evaluate long-term strategic options for the regulatory services business could result in several potential directions for the business, which could potentially have a significant impact on operations.

Future Outlook

The company expects income tax expense to increase over time as it grows more profitable. It plans to continue investing in scientific talent, sales and marketing, research and development (including AI integration), and other operational and administrative functions, anticipating an increase in headcount and total operating expenses. Management believes existing sources of liquidity will be sufficient to meet working capital, capital expenditures, and contractual obligations for the foreseeable future. The company is currently evaluating the impact of the 'One Big Beautiful Bill Act' (OBBBA) on its tax disclosures.

Management Comments

• Our goal is to enable the life science industry to use data, modeling, and analytics to make better decisions during drug development and commercialization to increase productivity rates and vastly reduce development costs.
• We believe that AI predictive models will continue to enhance the accuracy and usefulness of biosimulation models and will be utilized broadly across drug development.
• With continued innovation in and adoption of our biosimulation software, technology, and services, we believe more life science companies worldwide will leverage more of our end-to-end platform to reduce cost, accelerate speed to market, and ensure safety and efficacy of medicines for all patients.
• We continually seek and assess a range of highly focused opportunities in our immediately addressable market and in related adjacent markets, whether through acquisitions, licenses, or partnerships.

Industry Context

The biopharmaceutical industry faces high R&D costs, with over $270 billion spent annually and an average of $6.2 billion per FDA-approved drug, including failures. Certara's biosimulation and Model-Informed Drug Development (MIDD) solutions are gaining increasing acceptance from regulatory bodies like the FDA and European Medicines Agency, driving demand. The new U.S. federal administration's focus on pharmaceutical industry reform, particularly drug pricing and accelerated drug approval, presents both opportunities and challenges. The recent U.S. federal government shutdown could disrupt regulatory processes, potentially impacting drug development timelines across the industry.

Comparison to Industry Standards

• Customers leveraging Certara's solutions have been associated with 90% or more of all new drug approvals by the FDA since 2014, indicating a strong market presence and impact on successful drug development outcomes.
• The company's biosimulation and MIDD strategies aim to significantly reduce the average pharmaceutical industry R&D spending of over $270 billion annually and the average cost of $6.2 billion per FDA-approved drug, including failures, as cited in 'Analysis of pharma R&D productivity a new perspective needed' on Drug Discovery Today.
• No specific comparable companies or projects were detailed in the filing for a direct competitive assessment against industry benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• There have been no material changes to legal proceedings as previously disclosed in the 2024 Annual Report.

Stakeholder Impact

• Shareholders: Positive impact from increased net income, strong operating cash flow, and a stock repurchase program. Potential negative impact from macroeconomic conditions, regulatory delays, and risks to future growth.
• Employees: Expected headcount growth due to investments in scientific talent, sales, marketing, and R&D. Executive Officer Severance Policy provides benefits for executive officers.
• Customers: Continued strong demand for technology-enabled services and software products, with expansion of relationships. Potential for delays in drug approvals due to government shutdown could indirectly affect biopharmaceutical customers.
• Creditors: Debt refinancing and interest rate swaps aim to mitigate interest rate risk. The company remains in compliance with debt covenants.
• Regulatory Authorities: Continued collaboration and use of Certara's software by 23 global drug regulatory agencies. Potential for disruptions due to government shutdown.

Next Steps

• Continue to invest in scientific talent to expand ability to deliver solutions across the drug development spectrum.
• Continue to invest in sales and marketing to promote solutions to new and existing customers and in existing and expanded geographies.
• Continue to invest in research and development to support existing solutions and innovate new technology, including AI integration.
• Continue to invest in other operational and administrative functions to support expected growth.
• Continue to invest in complementary businesses, including through acquisitions.
• Evaluate the impact of the 'One Big Beautiful Bill Act' (OBBBA) on tax disclosures within consolidated financial statements.
• Monitor the impacts of the U.S. federal government shutdown on operations and financials.
• Continue to assess a range of highly focused opportunities in immediately addressable and related adjacent markets, whether through acquisitions, licenses, or partnerships.
• Continue the review process initiated in 2024 to evaluate the long-term strategic options for the regulatory services business.

Key Dates

Recommendation

Certara's Q3 2025 results show solid revenue growth and a return to net profitability, driven by strategic acquisitions and strong demand for its biosimulation solutions. The company's robust operating cash flow and ongoing share repurchase program are positive indicators for shareholder value. However, the net retention rate saw a slight decline, and the potential for regulatory delays due to government shutdowns, coupled with the ongoing evaluation of the 'One Big Beautiful Bill Act' and strategic options for the regulatory services business, introduce elements of uncertainty. While the company's market position and innovation in AI are strong, these external and internal factors warrant a 'hold' recommendation until further clarity on their impact emerges.

Keywords

Certara, biosimulation, drug discovery, biopharmaceutical, SEC filing, 10-Q, financial results, software, services, AI, machine learning, healthcare technology, pharmaceutical R&D, corporate governance, stock repurchase, debt refinancing, Chemaxon, regulatory science